A Randomized, Open-label, Crossover Phase 1 Study to Evaluate the Bioequivalence Following a Single Oral Dose Administration of SYR-472 25mg and 50mg Tablets in Healthy Adult Male Subjects
Phase of Trial: Phase I
Latest Information Update: 25 May 2016
At a glance
- Drugs Trelagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Takeda
- 25 May 2016 The time frames of the primary endpoints have changed from 21 days to "Day 1: pre dose (within 3 hours prior to dosing), and at multiple time points (up to 168 hours) post dose in each period"
- 08 Apr 2016 Status changed from not yet recruiting to completed.
- 02 Mar 2015 New trial record